Prof Sandro Porceddu
Honorary Professorial Fellow
The Sir Peter MacCallum Department of Oncology
278 Scholarly works
2 Projects
HIGHLIGHTS
2026
Journal article
Will Artificial Intelligence Crack the Diagnostic Code of Cutaneous T-Cell Lymphomas Amongst Community-Based Physicians?
DOI: 10.5826/dpc.1604a71422026
Journal article
C-Post Study of Adjuvant Cemiplimab for High-Risk Cutaneous Squamous Cell Carcinoma: Impact of Adjuvant Radiotherapy on Disease-Free Survival
DOI: 10.1016/j.ijrobp.2026.06.0862026
Journal article
Impact of User-Defined vs. Automatic Static Angle Modulated Port Selections for VMATp Nasopharyngeal Carcinoma Treatment
DOI: 10.1016/j.ijrobp.2026.06.16992026
Journal article
Efficient deep learning-driven workflows for accelerated single-fraction radiation therapy planning of a solitary tumour in the lung.
DOI: 10.1016/j.phro.2026.1010822026
Journal article
Patient Reported Symptom Trajectories during and after Radiotherapy (RT) for Human Papillomavirus-Associated Oropharyngeal Cancer (HPVOPC): A TROG 12.01 Secondary Analysis
DOI: 10.1016/j.ijrobp.2026.06.5542025
Research grants (ARC, NHMRC, MRFF)
Novel Treatment of Radiation Associated Dysphagia With Statins (TRADstat)
2024
Research grants (other domestic)
Next-Generation Radiotherapy Treatment Planning With Artificial Intelligence
RECENT SCHOLARLY WORKS
2026
Journal article
Radiation Therapy Target Objectives for Tonsillar Cancer Treated With Unilateral Radiation Therapy—A Replanning Study From TROG 12.01
DOI: 10.1016/j.ijrobp.2025.12.0582026
Journal article
Sensorineural hearing outcomes in HPV-positive oropharyngeal cancer: a secondary analysis of the TROG 12.01 randomized trial (SHOUT)
DOI: 10.1016/j.radonc.2026.1115502026
Journal article
C-POST study of adjuvant cemiplimab for high-risk cutaneous squamous cell carcinoma (CSCC): Disease-free survival (DFS) analyses per high-risk criteria and per start time after radiotherapy.
DOI: 10.1200/jco.2026.44.16_suppl.60832026
Journal article
Clinical and Patient-Reported Outcomes (PROs) in C-POST: Phase 3 Trial of Adjuvant Cemiplimab (Cemi) vs Placebo (Pbo) for High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
DOI: 10.1016/j.ijrobp.2026.02.1432026
Journal article
Clinical and Patient-Reported Outcomes in C-POST: Phase 3 Trial of Adjuvant Cemiplimab versus Placebo for High-Risk Cutaneous Squamous Cell Carcinoma
DOI: 10.1016/j.ejcskn.2026.100962